Skip to content
Screener

Vor Biopharma VOR Financing Cash Flow

Financing Cash Flow at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
-$8.78B-54.9%
Amgen logo
AmgenAMGN
-$1.48B+44.6%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
-$538.8M+20.8%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$739.41M+459,161%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$1.1M+195%
Vera Therapeutics logo
Vera TherapeuticsVERA
$3.94M+157%

Other financials

Income statement

See full
Operating income-$35.2M-5.6%
Net income-$219.6M-576%
EPS (diluted)-$5.11+1.9%

Balance sheet

See full
Cash & equivalents$169.9M+239%
Total debt$2.9M-90.5%
Total equity-$150.4M-328%
Total assets$506.7M+364%

Cash flow

See full
Operating cash flow-$38.2M-23.1%
CapEx$48.0K-79.2%
Free cash flow-$38.3M-22.4%

Valuation

See full
Market cap$1.28B+416%
Enterprise value$1.12B+902%

Returns & leverage

See full
Return on equity-125.4%+671pp
Debt / equity0.5×+0.2×
Current ratio31.1×+27.3×

Where this comes from

Reported directly by Vor Biopharma in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Vor Biopharma’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 8:31 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-220689
(in thousands)Three Months Ended March 31, 2026Three Months Ended March 31, 2025
Payment of issuance costs related to private placement(127)(551)
Repurchases of shares for tax withholdings upon vesting of restricted stock unit awards(2)(55)
Proceeds from issuance of common stock in private placement74,999
Net cash provided by (used in) financing activities74,870(606)
Net decrease in cash, cash equivalents and restricted cash equivalents(226,613)(31,902)
Cash, cash equivalents and restricted cash equivalents, beginning of period$396,654$84,362
Cash, cash equivalents and restricted cash equivalents, end of period$170,041$52,460
Supplemental disclosure of non-cash activities

Item 1. Financial Statements (Unaudited).

FAQ

What is Vor Biopharma's financing cash flow?
Vor Biopharma (VOR) reported financing cash flow of $74.87M in Q1 2026.
How has Vor Biopharma's financing cash flow changed year-over-year?
Vor Biopharma's financing cash flow increased by 12454.8% year-over-year, from -$606K to $74.87M.
What is the long-term trend for Vor Biopharma's financing cash flow?
Over 4 years (2021 to 2025), Vor Biopharma's financing cash flow has grown at a 21.2% compound annual growth rate (CAGR), from $233.36M to $503.81M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Vor Biopharma's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude